INTEGRATING MOLECULAR BIOLOGY WITH CANCER MOLECULAR IMAGING AND THERANOSTICS

将分子生物学与癌症分子成像和治疗诊断学相结合

• 批准号: 10493422
• 负责人: Balaji Krishnamachary
• 金额: $ 9.34万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-23 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10493422
• 关键词: Award; Doctor of Philosophy; Environment; Funding; Gene Silencing; Genes; Genetic Transcription; Goals; Grant; Hypoxia; Hypoxia Inducible Factor; In Vitro; Laboratory Research; Malignant Neoplasms; Mentors; Methods; Mission; Molecular; Molecular Biology; Molecular Biology Techniques; Monitor; Neoplasm Metastasis; Pathology; Postdoctoral Fellow; Productivity; Renal carcinoma; Research; Research Personnel; Research Project Grants; Small Interfering RNA; Specialist; Talents; Training; Work; cancer imaging; career; hypoxia inducible factor 1; in vivo Cellular and Molecular Imaging Centers; medical schools; molecular imaging; nanoparticle delivery; pediatric department; post-doctoral training; programs; recruit; small hairpin RNA; theranostics; tumor; tumor microenvironment; tumor progression

Y at ha A hu Vai ryo The purpose of this R50 application is to provide 6 months effort for Dr. Balaji Krishnamachary as a Research Specialist working with Dr. Bhujwalla as Unit Director. Dr. Krishnamachary was awarded his PhD in 1995, following which he completed his postdoctoral training, first in the Department of Pathology at ULCA from 1998- 2000, and subsequently in the Department of Pediatrics at Johns Hopkins School of Medicine from 2000-2006. During his postdoctoral training in the Department of Pediatrics, Dr. Krishnamachary worked with Dr. Gregg Semenza on hypoxia and the hypoxia inducible factor (HIF)-1. He gained significant expertise in constructing both siRNA and shRNA, establishing a retroviral delivery method to silence the transcription factor hypoxia inducible factor-1 (HIF-1) in vitro in renal carcinoma, and was trained in various molecular biology techniques to interrogate the transcriptional activity of genes involved in the progression of cancer. Dr. Krishnamachary joined Dr. Bhujwalla’s Cancer Imaging Research Program in 2006 as a Research Associate. Dr. Krishnamachary is a laboratory research-oriented investigator with an outstanding track record in integrating molecular biology with molecular imaging and theranostics. As an exceptionally talented molecular biologist who has been actively pursuing research within Dr. Bhujwalla’s NCI funded molecular imaging and theranostics research program, this opportunity is particularly relevant for Dr. Krishnamachary. He has shown clear evidence of productivity and research excellence in molecular biology applied to molecular imaging. Dr. Krishnamachary will continue to integrate his molecular biology expertise within the cancer molecular imaging research program directed by Dr. Bhujwalla, with the goal of making significant contributions to cancer molecular imaging that is relevant to the NCI mission. The Unit Director, Dr. Bhujwalla, has been funded continuously by the NCI since 1997. Dr. Krishnamachary was recruited by her in 2006 to provide molecular biology expertise to her molecular imaging research program following the funding of an NCI P50 grant (JHU ICMIC Program) that she held from 2003-2017. Dr. Bhujwalla currently holds an NCI R35 Outstanding Investigator Award on ‘Molecular Imaging and Theranostics of Cancer’ that is funded until 2024. Since the previous R50 submission, Dr. Bhujwalla competitively renewed her R01 titled ‘Hostile Environments promote Invasion and Metastasis’, and was awarded a new R01 on ‘The Tumor Microenvironment in Nanoparticle Delivery and Function’. Dr. Krishnamachary’s efforts are closely integrated and critical to the scientific research of these grants providing clear evidence that Dr. Bhujwalla is strongly committed to Dr. Krishnamachary and his research. She has worked closely with Dr. Krishnamachary since 2006 and will continue to be responsible for the planning, direction, monitoring, and execution of the NCI funded research together with Dr. Krishnamachary. Dr. Bhujwalla’s purpose in supporting this application to the best of her ability is to achieve a stable environment for Dr. Krishnamachary and to advance his career.

Yat Ha AhuVai Ryo 此R50申请的目的是为Balaji Krishnamachary博士作为研究人员提供6个月的工作 与布杰瓦拉博士共同担任股长的专家。Krishnamachary博士于1995年获得博士学位， 之后，他完成了博士后培训，1998年第一次在ULCA病理学系- 2000年在约翰霍普金斯大学医学院儿科就诊，随后于2000年至2006年在约翰霍普金斯大学医学院儿科就诊。 在儿科博士后培训期间，Krishnamachary医生与Gregg医生合作 塞门沙对缺氧和缺氧诱导因子-1的影响。他在建造建筑方面获得了丰富的专业知识 SiRNA和shRNA，建立一种逆转录病毒传递方法来沉默转录因子缺氧 诱导因子-1(HIF-1)在体外对肾癌的作用，并接受了各种分子生物学技术的培训，以 询问与癌症进展有关的基因的转录活性。 Krishnamachary博士于2006年加入布杰瓦拉博士的癌症成像研究计划，担任研究助理。 Krishnamachary博士是一名以实验室研究为导向的研究员，在整合 分子生物学与分子成像和治疗学。作为一名才华横溢的分子生物学家 一直在布杰瓦拉博士的NCI资助的分子成像和治疗学领域内积极开展研究 研究计划，这个机会对Krishnamachary博士来说特别重要。他已经拿出了明确的证据 将分子生物学的生产力和卓越研究成果应用于分子成像。Krishnamachary博士 将继续将他的分子生物学专业知识整合到癌症分子成像研究计划中 由布杰瓦拉博士指导，目标是对癌症分子成像做出重大贡献，即 与国家情报局的任务有关。 该股股长布杰瓦拉博士自1997年以来一直由国家情报局提供经费。Krishnamachary博士是 2006年被她聘用，为她的分子成像研究项目提供分子生物学专业知识 在2003-2017年间，她获得了NCI P50赠款(JHU ICMIC计划)的资助。布杰瓦拉医生 目前在癌症的分子成像和遗传学方面拥有NCI R35杰出研究人员奖 这笔资金将持续到2024年。自上次提交R50以来，布杰瓦拉博士竞争性地更新了她的R01，标题为 《恶劣环境促进侵袭和转移》，并因《肿瘤》获得新的R01奖 纳米颗粒传递和功能中的微环境。Krishnamachary博士的努力是紧密结合的 对这些赠款的科学研究至关重要，提供了明确的证据表明布杰瓦拉博士强烈 致力于Krishnamachary博士和他的研究。自那以后，她一直与克里希纳马查里博士密切合作 2006年，并将继续负责规划、指导、监测和执行NCI资助的 与Krishnamachary博士共同研究。布杰瓦拉博士全力支持这项申请的目的 她的能力是为Krishnamachary博士创造一个稳定的环境，并推动他的职业生涯。